Status: Recruiting
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)
Participants needed: 20
Trial details
Phase: Phase 1Age: 2+Biological sex: AllType: InterventionalSponsor: OneChain ImmunotherapeuticsUpdated: Mar 11, 2026Locations: 2
Eligibility criteria
Children older than 2 years or adults, male and female in both groups. [+6]
Limiting organ dysfunction, such as uncontrolled cardiac (e.g., depressed left v... [+9]